Thursday, September 5, 2013
• Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it reached enrollment of 50 percent of the patients planned in its randomized Phase III trial of Iclusig (ponatinib) in adults with newly diagnosed chronic myeloid leukemia (CML).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.